Efficacy of repeated cycles of chemo-immunotherapy with thymosin α1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery

Cancer Immunology Immunotherapy

Volumn 48, Issue 4, 1999, Pages 172-178

  Silecchia, Gianfranco ^a   Guarino, Enrico ^a   Sinibaldi Vallebona, Paola ^b   Pierimarchi, Pasquale ^c   Restuccia, Angelo ^a   Spaziani, Erasmo ^a   Bernard, Paola ^c   Tuthill, Cynthia ^d   Garaci, Enrico ^b   Rasi, Guido ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CNR   (Italy)

^d SciClone Pharmaceuticals Inc   (United States)

Author keywords

5 FU; Interleukin 2 Survival; T cells; Thymosin 1

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FLUOROURACIL; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2; THYMOSIN ALPHA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HELPER CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FLUOROURACIL; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; MALE; RATS; RATS, INBRED STRAINS; RECEPTORS, INTERLEUKIN-2; THYMOSIN;

EID: 0032837362     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050562     Document Type: Article

References (25)

1. 1. Cordel S, Heymann MF, Boisteau O, Oliver L, Le Pendu J, Gregoire M, Meflah K (1997) 5-Fluorouracil-resistant colonic tumors are highly responsive to sodium butyrate/interleukin-2 bitherapy in rats. Int J Cancer 73:924
2. 2. Dalgleish AG (1994) The role of IL-2 in gene therapy. Gene Ther 1:83
3. 3. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E (1989) Synergistic effect of thymosin alpha-1 and alpha-beta interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol 11:443
4. 4. Garaci E, Pica F, Mastino A, Palamara AT, Belardelli F, Favalli C (1993) Anti-tumor effect of thymosin a1/interleukin-2 or thymosin a1/interleukin a-b, following cyclophosphamide, in mice injected with highly metastatic Friend erythro-leukemia cells. J Immunother 13:7
5. 5. Hawkins MJ (1993) Interleukin-2 antitumor and effector cell responses. Semin Oncol 20 [Suppl 9]:52
6. 6. Kemeny NE (1995) Regional chemotherapy of colorectal cancer. Eur J Cancer 31A: 1271
7. 7. Labianca R, Pessi MA, Zamparelli G (1997) Treatment of colorectal cancer: Current guidelines and future prospects for drug therapy. Drugs 53:593
8. 8. Leichtling KD, Serrate SA, Sztein MB (1990) Thymosin alpha 1 modulates the expression of high-affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 12:19
9. 9. Lesuffleur T, Kornowski A, Luccioni C, Muleris M, Barbat A, Beautmain J, Dussaulx E, Dutrillaux B, Zweibaum A (1991) Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation. Int J Cancer 49:721
10. 10. Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E (1991) Thymosin a1 potentiates interleukin-2-induced cytotoxic activity in mice. Cell Immunol 133:196
11. 11. Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, Garaci E (1992) Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 50:493
12. 12. McCall JL, Jorgensen JO, Morris DL (1995) Hepatic artery chemotherapy for colorectal liver metastases. Aust N Z J Surg 65:383
13. 13. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT (1997) Sensitization of cancer cell treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89:783
14. 14. Pica F, Fraschetti M, Matteucci C, Tuthill C, Rasi G (1998) High doses of Thymosin Alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res 18:3571
15. 15. Prete SP, Aquino A, Masci G, Orlando L, Giuliani A, De Santis S, De Vecchis L, De Filippi R, Greiner JW, Bonmassar E, Graziani G (1996) Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil. J Pharmacol Exp Ther 279:1574
16. 16. Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S, Garaci E (1994) Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 57:701
17. 17. Rasi G, Pierimarchi P, Bernard P, Sinibaldi-Vallebona P, Garaci E (1996) Tumour liberated proteins (TLP): characterisation of a new tumour associated antigen of non-small cell lung cancer. Anticancer Res 16:1064
18. 18. Rosenberg SA (1988) Immunotherapy of cancer using interleukin-2 - current status and future prospects. Immunol Today 9:58
19. 19. Serrate SA, Schulof RS, Leondardis L, Goldstein AL, Sztein M (1987) Modulation of human natural killer cell cytotoxic activity; lymphokine production and interleukin-2 receptor expression by thymic hormones. J Immunol 139:2338
20. 20. Sutanto-Ward E, Sigurdson ER, Tremiterra S, Linger R, Chapman D, Niedzwiecki D (1992) Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing. Surg Oncol 1:87
21. 21. Sztein MB, Serrate SA, Goldstein AL (1986) Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 83:6107
22. 22. Tomita Y, Imal T, Katagiri A, Kimura M, Saitoh K, Sato S (1993) 5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at the post-binding stage of the lytic cycle. Cancer Lett 75:27
23. 23. Vahrmeijer AL, Dierendonck JH van, Velde CJ van de (1995) Treatment of colorectal cancer metastases confined to the liver. Eur J Cancer 31A: 1238
24. 24. Valeri A, Mini E, Tonelli P, Veneri F, Neri B, Borrelli D, Mazzei T (1994) Intra-arterial hepatic chemotherapy with 5-fluorouracil and 5-methyltetrahydrofolate in the treatment of unresectable liver metastases from colorectal cancer. Anticancer Res 14:2215
25. 25. Zeng ZS, Zhang ZF, Sigurdson ER (1995) Toxicity study of hepatic artery infusion chemotherapy with massive dose FUDR in rats. Surg Oncol 4:147